Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 255

Results For "Global"

4845 News Found

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions with food allergies
Clinical Trials | February 28, 2024

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions with food allergies

The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies


Zydus receives WHO prequalification for Miltefosine formulation and API
Drug Approval | February 26, 2024

Zydus receives WHO prequalification for Miltefosine formulation and API

Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies


Orchid Pharma's 'Exblifep' receives USFDA approval
Drug Approval | February 24, 2024

Orchid Pharma's 'Exblifep' receives USFDA approval

Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA


VP Dhankhar emphasizes need for ethical standards in the medical profession at APICON-2024
News | February 24, 2024

VP Dhankhar emphasizes need for ethical standards in the medical profession at APICON-2024

The Vice President also highlighted the importance of preventive healthcare and fitness


Aptar Digital Health acquires Healint to broaden neurology portfolio
News | February 23, 2024

Aptar Digital Health acquires Healint to broaden neurology portfolio

The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment


AstraZeneca completes acquisition of Gracell
News | February 23, 2024

AstraZeneca completes acquisition of Gracell

The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F


Moderna posts Q4 2023 revenue at US$ 2.8 billion
News | February 23, 2024

Moderna posts Q4 2023 revenue at US$ 2.8 billion

Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance


Dr Mandaviya addresses WHO’s public launch event of GIDH
News | February 22, 2024

Dr Mandaviya addresses WHO’s public launch event of GIDH

Global Initiative on Digital Health (GIDH) was launched by the WHO and the Government of India during the G20 Health Working Group meeting in Gandhinagar last year


Pfizer and AIF’s Project Parivartan demonstrates progress in addressing antimicrobial resistance
News | February 22, 2024

Pfizer and AIF’s Project Parivartan demonstrates progress in addressing antimicrobial resistance

Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms


Evonik, University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery
News | February 18, 2024

Evonik, University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery

Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery